Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

The global antibody drug conjugates market size was US$ 4,990.8 million in 2021. The global antibody drug conjugates s market size is forecast to reach US$ 33,150.3 million by 2030, growing at a CAGR ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

North America dominated the Antibody Drug Conjugates (ADC) market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period. By ...

Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...

NEW YORK, February 24, 2025--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, ...

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports. In the recent years, antibody-drug conjugates (ADC) have been gradually gaining ...

The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...